Generic substitution policy, an incentive approach

Generic substitution policy has been adopted in several countries in order to control health expenditures. Using a model based on incentives, this work aims to analyze the response of doctors and pharmaceutical companies to the implementation of this policy. It is shown that after the implementation of GSP, the effort of doctor’s convincing the patient to take generics increase or decrease depending on his level of concern for patient well-being; pharmaceutical companies decrease the amount of detailing and the market share of generics tends to increase.

[1]  Tracy L. Regan.  Generic entry, price competition, and market segmentation in the prescription drug market , 2008 .

[2]  A. Wazana,et al.  Physicians and the pharmaceutical industry: is a gift ever just a gift? , 2000, JAMA.

[3]  John Hudson,et al.  Generic take-up in the pharmaceutical market following patent expiry A multi-country study , 2000 .

[4]  M. Petzold,et al.  What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden , 2005, Pharmacoepidemiology and drug safety.

[5]  H. Mikkola,et al.  Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  Elias Mossialos,et al.  An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. , 2005, The International journal of health planning and management.

[7]  W. Bearden,et al.  Generic Drugs: Consumer, Pharmacist and Physician Perceptions of the Issues , 1980 .

[8]  G. Harris.  As doctor writes prescription, drug company writes a check. , 2004, The New York times on the Web.

[9]  Joel Lexchin,et al.  The effect of generic competition on the price of brand-name drugs. , 2004, Health policy.

[10]  Donald J. Birkett,et al.  Generics - equal or not? , 2003 .

[11]  Ville Aalto-Setälä.  The impact of generic substitution on price competition in Finland , 2008, The European Journal of Health Economics.

[12]  P. Halfon,et al.  Determinants of generic drug substitution in Switzerland , 2011, BMC health services research.

[13]  Kurt R. Brekke,et al.  Margins and Market Shares: Pharmacy Incentives for Generic Substitution , 2010, SSRN Electronic Journal.

[14]  F. Tediosi,et al.  A comparative analysis of generics markets in five European countries. , 2000, Health policy.

[15]  P. Zweifel,et al.  Generic substitution, financial interests, and imperfect agency , 2013, International Journal of Health Care Finance and Economics.

[16]  K. Bennett,et al.  The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland , 2005, The European Journal of Health Economics.

[17]  Anna Merino-Castelló,et al.  Demand for Pharmaceutical Drugs: A Choice Modelling Experiment , 2004 .

[18]  C. Gaither,et al.  Consumers' Views on Generic Medications , 2001 .

[19]  G. Perry.  The European Generic Pharmaceutical Market in Review: 2006 and Beyond , 2006 .

[20]  M. Hassali,et al.  The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use , 2013, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[21]  J. Hellerstein,et al.  The importance of the physician in the generic versus trade-name prescription decision. , 1998, The Rand journal of economics.

[22]  Fiona M. Scott Morton.  Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry , 2000 .